Compare Agilysys Inc (AGYS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Novartis AG — how do they compare? Agilysys Inc trades at $106.06 (market cap $3.02B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 98.7× Agilysys Inc's market cap, and Novartis AG pays a 3.02% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | NVS | |
|---|---|---|
Market Cap | $3.02B | $298.18B |
Sector | Technology | Health |
52-Week High | $141.12 | $168.62 |
52-Week Low | $62.19 | $119.31 |
Enterprise Value | $2.92B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $108.58, up 0.93% with strong bullish momentum supported by recent earnings beats and positive analyst sentiment. The stock shows robust fundamental performance with Q1 2026 EPS of $0.63 beating expectations and record subscription revenue growth. Technical indicators suggest bullish momentum with the current price near pivot point resistance at $108, while moving averages signal continued upward trend potential.
The outlook remains positive with 100% analyst buy ratings and a $118.33 consensus price target representing 9% upside. Key catalysts include continued subscription growth and Marriott deployment progress, though elevated valuation multiples (P/E 70.45) and competitive pressures in hospitality software present risks requiring monitoring of execution consistency.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
